Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Antitumor activity of human CD34+ cells expressing membrane-bound tumor necrosis factor-related apoptosis-inducing ligand.

Carlo-Stella C, Lavazza C, Di Nicola M, Cleris L, Longoni P, Milanesi M, Magni M, Morelli D, Gloghini A, Carbone A, Gianni AM.

Hum Gene Ther. 2006 Dec;17(12):1225-40.

PMID:
17107337
2.

Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature.

Lavazza C, Carlo-Stella C, Giacomini A, Cleris L, Righi M, Sia D, Di Nicola M, Magni M, Longoni P, Milanesi M, Francolini M, Gloghini A, Carbone A, Formelli F, Gianni AM.

Blood. 2010 Mar 18;115(11):2231-40. doi: 10.1182/blood-2009-08-239632. Epub 2010 Jan 14.

3.

Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model.

Rossini A, Giussani M, Giacomini A, Guarnotta C, Tagliabue E, Balsari A.

Breast Cancer Res Treat. 2012 Nov;136(2):457-67. doi: 10.1007/s10549-012-2281-4. Epub 2012 Oct 11.

4.

Induction of death receptor 5 expression in tumor vasculature by perifosine restores the vascular disruption activity of TRAIL-expressing CD34(+) cells.

Giacomini A, Righi M, Cleris L, Locatelli SL, Mitola S, Daidone MG, Gianni AM, Carlo-Stella C.

Angiogenesis. 2013 Jul;16(3):707-22. doi: 10.1007/s10456-013-9348-7. Epub 2013 Apr 20.

PMID:
23605004
5.

Targeting TRAIL agonistic receptors for cancer therapy.

Carlo-Stella C, Lavazza C, Locatelli A, Viganò L, Gianni AM, Gianni L.

Clin Cancer Res. 2007 Apr 15;13(8):2313-7. Review.

6.

YM155 sensitizes triple-negative breast cancer to membrane-bound TRAIL through p38 MAPK- and CHOP-mediated DR5 upregulation.

Pennati M, Sbarra S, De Cesare M, Lopergolo A, Locatelli SL, Campi E, Daidone MG, Carlo-Stella C, Gianni AM, Zaffaroni N.

Int J Cancer. 2015 Jan 15;136(2):299-309. doi: 10.1002/ijc.28993. Epub 2014 Jun 5.

8.

Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma.

Yan C, Li S, Li Z, Peng H, Yuan X, Jiang L, Zhang Y, Fan D, Hu X, Yang M, Xiong D.

Mol Pharm. 2013 Jan 7;10(1):142-51. doi: 10.1021/mp300261e. Epub 2012 Dec 7.

PMID:
23121392
9.

Antitumor activity of TRAIL recombinant adenovirus in human malignant glioma cells.

Kim KU, Seo SY, Heo KY, Yoo YH, Kim HJ, Lee HS, Choi SS, Hwang TH, Lee HJ.

J Korean Med Sci. 2005 Dec;20(6):1046-52.

10.

Suppressing orthotopic pancreatic tumor growth with a fiber-modified adenovector expressing the TRAIL gene from the human telomerase reverse transcriptase promoter.

Jacob D, Davis J, Zhu H, Zhang L, Teraishi F, Wu S, Marini FC 3rd, Fang B.

Clin Cancer Res. 2004 May 15;10(10):3535-41.

11.

Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.

Fecker LF, Rückert S, Kurbanov BM, Schmude M, Stockfleth E, Fechner H, Eberle J.

Hum Gene Ther. 2011 Apr;22(4):405-17. doi: 10.1089/hum.2010.108. Epub 2011 Feb 16.

PMID:
20977303
12.

Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy.

Grisendi G, Bussolari R, Cafarelli L, Petak I, Rasini V, Veronesi E, De Santis G, Spano C, Tagliazzucchi M, Barti-Juhasz H, Scarabelli L, Bambi F, Frassoldati A, Rossi G, Casali C, Morandi U, Horwitz EM, Paolucci P, Conte P, Dominici M.

Cancer Res. 2010 May 1;70(9):3718-29. doi: 10.1158/0008-5472.CAN-09-1865. Epub 2010 Apr 13.

13.

Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.

Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W, Teraishi F, Ji L, Fang B.

Clin Cancer Res. 2006 Sep 1;12(17):5224-30.

15.

Cisplatin enhances the antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand gene therapy via recruitment of the mitochondria-dependent death signaling pathway.

Shamimi-Noori S, Yeow WS, Ziauddin MF, Xin H, Tran TL, Xie J, Loehfelm A, Patel P, Yang J, Schrump DS, Fang BL, Nguyen DM.

Cancer Gene Ther. 2008 Jun;15(6):356-70. doi: 10.1038/sj.cgt.7701120. Epub 2008 Feb 29.

PMID:
18309355
16.

Cancer gene therapy using a novel secretable trimeric TRAIL.

Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW.

Gene Ther. 2006 Feb;13(4):330-8.

PMID:
16195699
17.
18.

Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model.

Yoo J, Choi S, Hwang KS, Cho WK, Jung CR, Kwon ST, Im DS.

J Gene Med. 2006 Feb;8(2):163-74.

PMID:
16144019
19.

Dual-targeted antitumor effects against brainstem glioma by intravenous delivery of tumor necrosis factor-related, apoptosis-inducing, ligand-engineered human mesenchymal stem cells.

Yang B, Wu X, Mao Y, Bao W, Gao L, Zhou P, Xie R, Zhou L, Zhu J.

Neurosurgery. 2009 Sep;65(3):610-24; discussion 624. doi: 10.1227/01.NEU.0000350227.61132.A7.

PMID:
19687708
20.

Supplemental Content

Support Center